Renewable Energy

AstraZeneca's Lynparza gets EU nod as first-line ovarian cancer maintenance treatment

Credit: REUTERS/Brendan McDermid

British drugmaker AstraZeneca Plc on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel's consent in April.

June 18 (Reuters) - British drugmaker AstraZeneca Plc AZN.L on Tuesday said its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel's consent in April.

Lynparza, being jointly developed by AstraZeneca along with U.S. drugmaker Merck & Co MRK.N, can now be used in patients who are in response following chemotherapy for BRCA-mutated ovarian cancer in Europe, AstraZeneca said.

BRCA genes are responsible for producing proteins which repair damaged DNA, and if the genes are mutated, they can cause cancer growth.

(Reporting by Pushkala Aripaka in Bengaluru; Editing by Bernard Orr)

((Pushkala.A@thomsonreuters.com; within UK: +44 20 7542 1810, outside UK: +91 80 6749 6633 ; Reuters Messaging: Pushkala.A.thomsonreuters.com@reuters.net; Twitter: @pushkala_a))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More